| Identification | Back Directory | [Name]
1-Piperazinepropanamide, N-[3,4-dihydro-3-[[4-hydroxy-1-[(3R)-1-oxo-3-phenylbutyl]-4-piperidinyl]methyl]-4-oxo-7-quinazolinyl]-4-methyl- | [CAS]
2305045-76-3 | [Synonyms]
1-Piperazinepropanamide, N-[3,4-dihydro-3-[[4-hydroxy-1-[(3R)-1-oxo-3-phenylbutyl]-4-piperidinyl]methyl]-4-oxo-7-quinazolinyl]-4-methyl- | [Molecular Formula]
C32H42N6O4 | [MOL File]
2305045-76-3.mol | [Molecular Weight]
574.71 |
| Chemical Properties | Back Directory | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [pka]
13.61±0.20(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
XL 188 is a potent and selective USP7 inhibitor with IC50 values of 90 nM and 193 nM for USP7 full-length and catalytic domain enzyme, respectively. XL 188 can be used in research of cancer[1]. | [Biological Activity]
XL188 is a highly selective and potent (IC50 90 nM) non covalent inhibitor of USP7 th at binds to the USP7 active site. XL188 facilitates degradation of HDM2and increases the levels of p53 and p21 in MCF7 cells. | [References]
[1] Stolte B, et, al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med. 2018 Aug 6;215(8):2137-2155. DOI:10.1084/jem.20171066 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|